WO1983003679A1 - Antibodies having dual specificities, their preparation and uses therefor - Google Patents
Antibodies having dual specificities, their preparation and uses therefor Download PDFInfo
- Publication number
- WO1983003679A1 WO1983003679A1 PCT/US1983/000525 US8300525W WO8303679A1 WO 1983003679 A1 WO1983003679 A1 WO 1983003679A1 US 8300525 W US8300525 W US 8300525W WO 8303679 A1 WO8303679 A1 WO 8303679A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- process according
- hybrid
- antibodies
- hapten
- Prior art date
Links
- 230000009977 dual effect Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 135
- 239000000427 antigen Substances 0.000 claims abstract description 121
- 102000036639 antigens Human genes 0.000 claims abstract description 121
- 108091007433 antigens Proteins 0.000 claims abstract description 121
- 230000008569 process Effects 0.000 claims abstract description 113
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 112
- 230000004927 fusion Effects 0.000 claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 19
- 230000000890 antigenic effect Effects 0.000 claims abstract description 15
- 231100000518 lethal Toxicity 0.000 claims abstract description 12
- 230000001665 lethal effect Effects 0.000 claims abstract description 12
- 238000003745 diagnosis Methods 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 74
- 102000004190 Enzymes Human genes 0.000 claims description 50
- 108090000790 Enzymes Proteins 0.000 claims description 50
- 239000002609 medium Substances 0.000 claims description 42
- 239000000523 sample Substances 0.000 claims description 29
- 229960003343 ouabain Drugs 0.000 claims description 28
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 claims description 27
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 claims description 27
- 244000166550 Strophanthus gratus Species 0.000 claims description 27
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 20
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 229960003087 tioguanine Drugs 0.000 claims description 9
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 claims description 8
- 229960005508 8-azaguanine Drugs 0.000 claims description 8
- 238000003018 immunoassay Methods 0.000 claims description 8
- 210000004989 spleen cell Anatomy 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 230000002427 irreversible effect Effects 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 230000000171 quenching effect Effects 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims description 4
- KKEBXNMGHUCPEZ-UHFFFAOYSA-N 4-phenyl-1-(2-sulfanylethyl)imidazolidin-2-one Chemical compound N1C(=O)N(CCS)CC1C1=CC=CC=C1 KKEBXNMGHUCPEZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 4
- 238000003375 selectivity assay Methods 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical group OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 claims description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 3
- 108010039491 Ricin Proteins 0.000 claims description 3
- 229950011321 azaserine Drugs 0.000 claims description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical group [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003896 aminopterin Drugs 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 3
- 229940104230 thymidine Drugs 0.000 claims 3
- KIXKVUVOLNIKSG-UHFFFAOYSA-N 1-oxo-4,7-dihydroimidazo[4,5-e][1,2,4]thiadiazin-3-amine Chemical compound O=S1NC(N)=NC2=C1NC=N2 KIXKVUVOLNIKSG-UHFFFAOYSA-N 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000087624 Monoclona Species 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- XEQLGWAGMYUVTR-UHFFFAOYSA-N O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1 XEQLGWAGMYUVTR-UHFFFAOYSA-N 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 description 39
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 34
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 34
- 238000003556 assay Methods 0.000 description 20
- 206010003445 Ascites Diseases 0.000 description 17
- 239000011324 bead Substances 0.000 description 13
- 229940097325 prolactin Drugs 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 102000003946 Prolactin Human genes 0.000 description 11
- 108010057464 Prolactin Proteins 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 10
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 9
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 230000001263 anti-prolactin effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000006601 Thymidine Kinase Human genes 0.000 description 6
- 108020004440 Thymidine kinase Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 229960004927 neomycin Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000005548 Hexokinase Human genes 0.000 description 5
- 108700040460 Hexokinases Proteins 0.000 description 5
- 229930193140 Neomycin Natural products 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 4
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 4
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 4
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 4
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000008857 Ferritin Human genes 0.000 description 3
- 108050000784 Ferritin Proteins 0.000 description 3
- 238000008416 Ferritin Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940000489 arsenate Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 229940064790 dilantin Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000000760 immunoelectrophoresis Methods 0.000 description 3
- 238000013198 immunometric assay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- FRTNIYVUDIHXPG-UHFFFAOYSA-N acetic acid;ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN FRTNIYVUDIHXPG-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- PPKPKFIWDXDAGC-IHWYPQMZSA-N (z)-1,2-dichloroprop-1-ene Chemical compound C\C(Cl)=C\Cl PPKPKFIWDXDAGC-IHWYPQMZSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 101100042648 Drosophila melanogaster sing gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 102100036473 Phosphoribosylformylglycinamidine synthase Human genes 0.000 description 1
- 101710082600 Phosphoribosylformylglycinamidine synthase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241001632427 Radiola Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001611093 Stimula Species 0.000 description 1
- 102100037409 Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 Human genes 0.000 description 1
- 101710116672 Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 arsenat arsenate dimer Chemical class 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- PPTXFSQSISUDAU-UHFFFAOYSA-M hydrogen sulfate;2-methyl-4-[(2-methylphenyl)diazenyl]benzenediazonium Chemical compound OS([O-])(=O)=O.CC1=CC=CC=C1N=NC1=CC=C([N+]#N)C(C)=C1 PPTXFSQSISUDAU-UHFFFAOYSA-M 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WFLQAMUOBIONDG-UHFFFAOYSA-N phenoxyarsonic acid Chemical compound O[As](O)(=O)OC1=CC=CC=C1 WFLQAMUOBIONDG-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- This invention relates to antibodies having du specificities. In another aspect it relates to immun diagnostic and immunotherapeutic processes. In y another aspect it relates to hybridomas and relat monoclonal antibody technology.
- the antigen-antibody reaction is already routine exploited in a variety of practical applications and being widely investigated to establish its value in othe as yet unproven, utilities.
- serum antibodi produced by a host animal's immune response to an i mun gen can be used in affinity purification procedures isolate the immunogen from solutions in which it i present in only minute quantities.
- the immunogen is a diseas associated antigen
- its presence in a patient's serum o other body fluid can be detected using immunoassay o immunometric techniques.
- detection of HBs using a radioimmunometric technique is the current metho of choice.
- serum antibodies to ferri tin obtained from New Zealand white rabbits and labele with 131l, have been reported as showing promise for th treatment of liver tumors. (See Order et al, Internation al Journal of Radiation Oncology, Biology and Physics, j 703 (1980)).
- Serum antibodies for example, those obtained fro rabbits, urine species or other mammals are "polyclonal in nature since the immune system of the host is stimula ted to produce a mixture of specific antibodies directe
- each antibody specie is distinct molecule and the differences in peptide sequen between different ' species affect their general specifici ties as well as the particular epitopes they recognize an their affinities for the antigen.
- a monoclonal antibod will have a constant specificity for a single site on th antigen molecules and a well defined affinity.
- T immortality of the hybridoma guarantees an almost u limited supply of the antibody it secretes and alleviat problems associated with variance in antibody titer a overall affinity from animal to animal used to produ serum antibodies.
- Monoclonal antibodies obtained fr hybridomas have, for example, been put to practic application in diagnostic kits. A selection of such ki is available from Hybritech, Inc., assignee of th application.
- An antibody molecule can generally be considered express a single specificity which is exhibited towar the immunogen to which the host's immune system respond by production of the antibody.
- the antibody is compos of two identical halves, each of which is comprised of heavy and light chain pair and each of which recognize the same antigenic determinant as the other.
- the fol lowing is a representation of the arrangement of heavy (H and light (L) chains in an antibody molecule:
- the -S-S- disulfide bridges which link the two (H chains together at the location of cysteine moieties ca usually be cleaved selectively j ⁇ n vitro by a mild reduc tion, and the half molecules disassociated by subsequen acidification. The half molecules can then be recombine
- OM (renatured), again in vitro, at neutral pH, the reassocia- tion taking place through non-covalent interaction. If antibodies of different specificities are sub ⁇ jected to a selective cleavage of the disulfide bridges between the heavy chains and conditions conducive to renaturation subsequently established, reassociation between half molecules may occur randomly to produce a population of antibodies, at least some of which are hybrids in that one half of an antibody molecule of one specificity combines with one half of an antibody molecule of a different specificity.
- hybrid antibodies can be obtained in the manner described above, the yields are often very low, the reactions used to make them difficult to reproduce and the hybrid antibodies usually suffer significant, irreversible denaturation. Such denaturation can reduce immunore- activity and would be expected to result in different metabolic characteristics in vivo. As a result, the hybrid antibody today remains largely a laboratory curi ⁇ osity which is difficult to obtain.
- Antibodies having dual specificities may also be prepared by conjugating pairs of intact antibodies, monoclonal or otherwise, using a variety of coupling or crosslinking agents such as protein A (from Staphylococcus aureus), carbodiimide and bifunctional compounds such as N-succinimidyl-3-(2-pyridyldithio) propionate to obt dimeric and higher antibody multimers to which each mem of the antibody pair contributes its specificity.
- protein A from Staphylococcus aureus
- carbodiimide and bifunctional compounds such as N-succinimidyl-3-(2-pyridyldithio) propionate to obt dimeric and higher antibody multimers to which each mem of the antibody pair contributes its specificity.
- F example, Mandoche et al have reported the formation multivalent antibodies having dual specificities, by sequential reaction of antibodies with protein A, wh have been shown to be capable of detecting cell surf antigens jLn vitro. See
- the present invention provides, among other things, novel, completely biological method for reliably obtaini hybrid monoclonal antibodies in good yields witho denaturation.
- hybrid antibody will be used to designate a sing antibody molecule having two different specificities. T individual specificities may be to antigenic determinan on two different antigens or to different antigen determinants (epitopes) on the same antigen. Furthermor unless otherwise indicated, the term "antigen" al embraces haptens.
- hybrid antibodies having a dual specificity are obtain by fusion of a hybridoma, preferably a selectively d structible hybridoma, which secretes an antibody against preselected antigenic determinant with a fusible B-lymph cyte or a second hybridoma, the B-lymphocyte or secon hybridoma secreting a second antibody against a differe antigenic determinant, to form a second generation hybri doma (hereinafter "polydoma").
- a hybridoma preferably a selectively d structible hybridoma, which secretes an antibody against preselected antigenic determinant with a fusible B-lymph cyte or a second hybridoma
- the B-lymphocyte or secon hybridoma secreting a second antibody against a differe antigenic determinant
- the ter “selectively destructible hybridoma” means a hybridom which lacks, or at least substantially lacks, the capabi ity of surviving in the medium in which the polydoma i cultured.
- the polydoma i addition secretes a high percentage of a monoclonal hybri antibody having a dual specificity, i.e., a capability t bind with either of the antigenic determinants recognize by the individual antibodies produced by the parent cell or with both determinants at the same time.
- the hybri monoclonal antibody obtained in this way has not suffere the undesireable denaturation which characterizes hybrid obtained from the process of chemical recombination o antibody half molecules. Furthermore, the process of th invention permits the hybrid to be obtained reliably a in large amounts.
- these processes employ a monoclonal antibody or polyclona antibodies having a first specificity against a targe antigen and a second specificity against a substance, fo example, another antigen or hapten, which permits diagnosis to be made of the target antigen or whic permits delivery of, or is itself, an agent which i lethal to the target antigen or the tissue with which i is associated.
- polydoma can be obtained according to the present inven tion which will secrete an antibody having one specificit for a target antigen and a second specificity for a moiet useful in diagnosis or therapy.
- antibod half molecules can be recombined using _in vitro chemica means or individual intact mono-specific antibodies can b coupled or crosslinked by chemical means to obtain anti body multi ers (which may be a dimer, trimer or highe multimer) having a dual specificity and having the same o a similar utility as a hybrid monoclonal antibody havin the same dual specificity made according to the presen invention.
- antibody includes anti ⁇ body fragments having immunochemical properties such as Fab or F(ab) 2 fragments.
- an object of the present invention is to obtain hybrid monoclonal antibodies reliably and in good yield that have not been denatured in the process of their preparation.
- Another object of the present invention is an im ⁇ proved process for obtaining hybrid monoclonal antibodies. Yet another object of this invention is to provide immunodiagnostic and immunotherapeutic processes which employ antibodies having a dual specificity.
- the process for obtaining a hybrid monoclonal antibody according to the present invention requires, as one parent, a hybridoma, and preferably a selectively destructible hybridoma, which secretes a monoclonal antibody against a preselected antigenic determinant or epitope.
- a selective destructible hybridoma as a parent has the advantage that it prevents the cells obtained by fusion of the selectively destructible hybridoma with a B-lymphocyte or a second hybridoma, i.e., the polydoma, from being over ⁇ grown by a population of the parent hybridoma when the cells obtained in the fusion process are cultured and to provide a means by which the polydoma cells can be isola ⁇ ted from parental hybridoma cells.
- hybri ⁇ domas useful in our invention can be obtained from hybri ⁇ domas secreting an antibody having one of the desired specificities made by the classic Kohler-Milstein process, i.e., hybridomas obtained by fusion of a myeloma cell and a B-lymphocyte such as that found in the spleen cells of a mouse.
- hybridoma is subjected to a back selection process to obtain the hybridoma which is selectively destructible.
- selective destructibility can be obtained by back selection to a hybridoma which lacks a genetic component which is necessary to its survival in a medium of choice in which the polydoma produced by the fusion can be cultured because of a genetic contribution from the fusion partner of the selectively destructible hybridoma, i.e., the B-lymphocyte or second hybridoma.
- the presently preferred back selection process involves culturing a hybridoma which secretes an antibody having one of the desired specificities to be incorporated into the hybrid antibody in a growth medium containing 8-azaguanine.
- a growth medium containing 8-azaguanine any cell which incorpora ⁇ tes 8-azaguanine and can, therefore, grow in the medium are ones which lack the enzyme hypoxanthine-guanine phosphoribosyl transferase (HPRT).
- HPRT hypoxanthine-guanine phosphoribosyl transferase
- a very similar process for back selection involves growing the hybridomas secreting the desired antibody in a medium containing 6-thioguanine, another analog of guanine toxic to the cell if incorporated into the DNA. Again, certain cells which will grow in this medium lack the HPRT enzyme and clones of these cells will necessarily be sensitive to HAT medium.
- Yet another process for back selection which can be used in the invention involves growing cells of the selected hybridoma cell line in a medium containing either of the thymine analogs 5-bromouracyl deoxyribose (BUdR) o 2-aminopurine. Only those cells lacking the enzym thymidine kinase (TK) can grow in a medium containin either of these two inhibitors. As in the case of cell lacking the enzyme HPRT, cells lacking TK will not grow i HAT medium.
- a different process for obtaining a selectivel destructible parent hybridoma involves irreversible enzym inhibition using metabolic inhibitors.
- metabolic inhibitors th so called K ca t. inhibitors are preferred.
- These inhibi tors are analogs of an enzyme's substrate which ar converted by the target enzyme into a highly reactiv molecule which reacts with the enzyme at its active sit resulting in irreversible inhibition of the enzyme.
- treatment of the selected hybridoma with a analog of glutamine such as azaserine or 5-diazo-5-oxa-L norleucine (DON) irreversibly inhibits the enzyme formyl- glycinamide ribonucleotide amidotransferase by formatio of a covalent bond with a cysteine residue at the enzyme's active site. This inhibition will ultimately result in cell death.
- the hybridoma can be rescued by fusion with the second parent of the polydoma which supplies the necessary enzyme.
- the selectively destruc- tible hybridoma is fused with complementary B-lymphocytes, typically obtained as spleen cells taken from a host which has previously been immunized with an antigen, which may be a hapten bound to a carrier protein, selected to cause the host to generate an immune response which produces antibodies having the second specificity desired in the hybrid antibody.
- an antigen which may be a hapten bound to a carrier protein
- the host is usually a mouse but species of rabbits, humans and other animals may also be used although interspecies fusion may exhibit a low order of stability.
- the process for immunizing such a host is, of course, well known and details need not be given here.
- Fusion of the selectively destructible hybridoma wit the B-lymphocytes to obtain the polydoma can be accom plished by combining the two groups of cells in a maxim containing an agent known to promote cell fusion such a polyethylene glycol or Sendi virus according to know methods.
- the cells are transferred to a maxim such as HAT medium for culturing.
- the B-lymphocytes wil survive for only a brief period of. time and the paren hybridoma cells cannot grow in the medium.
- th population of polydomas formed as a result of the fusion because of complementation of the parent hybridoma by th B-lymphocyte, for example, by a genetic contribution o the ability to make a missing enzyme such as HPRT or TK o by a direct contribution of an enzyme inhibited in th parent hybridoma, can be grown in the medium.
- Clones o individual polydomas are cultured and screened to selec those which secrete antibodies having the desired dua specificity.
- Clones of polydomas whose antibodie exhibit the desired dual specificity are further screene to select those whose second specificity, i.e., tha obtained from the B-lymphocytes, and affinity are mos desireable.
- the polydoma is obtained b fusing the selectively destructible hybridoma using suitable fusion agent with a second hybridoma which i also selectively destructible.
- the second parent hybri doma is obtained in the same manner as the first, i.e., b a process of back selection, irreversible enzyme inhibi tion or by any other suitable technique.
- the second hybridoma must be able to complement th first.
- the first selectively destructibl hybridoma lacks the enzyme HPRT
- the second must b capable of contributing to the polydoma a gene which wil enable the polydoma to express HPRT.
- th second selectively destructible hybridoma lacks the enzym
- OM TK the first must contribute a gene for TK to the poly doma. Similar complementarity between the two hybridoma must be present if irreversible inhibition of an enzym has been accomplished to confer selective destructibilit on them. ' It is also possible to use, as one hybridom parent, a hybridoma which has been subjected to a bac selection process, and, as the other, a hybridoma whic has been subjected to a process of enzyme inhibition The use of complementary selectively destructibl hybridomas as parents for the polydoma has the advantag that both parents can be selected on the basis of th specificities and affinities of the monoclonal antibod they produce whereas, in the case of fusion of a singl hybridoma with B-lymphocytes, no pre-fusion selectio among the B-lymphocytes to obtain those producing a antibody of the desired specificity and affinity can b made.
- Fusion of the two selectively destructible hybridoma can be accomplished using polyethylene glycol or usin other fusing agents, again according to known methods. After fusion, the cells are transferred to a growth maxim in which the two parents cannot grow, but in which th polydomas resulting from the fusion are capable of growt because of the complementary contributions of the parents.
- selection processes t obtain selectively destructible hybridomas for use as both of the hybridoma partners in a hybridoma-hybridoma fusion to form a polydoma.
- the necessity for the second hybridoma parent to be selectively destructible can be avoided by conferring both a dominant and a recessive marker on the first hybridoma parent.
- a presently pre ⁇ ferred method is HAT-ouabain selection.
- the drug ouabain is a specific inhibitor of the Na + -K + activated ATPase of the plasma membrane. That enzyme is responsible for the importation of K + into a cell and the export of Na + from the cell.
- Cells of a hybridoma previously back selected to confer selective destructibility, for example. HAT sensitivity are grown in ouabain medium to select for ouabain resistant cells. Clones of these cells will be HAT sensitive but ouabain resistant. By contrast, the hybridoma selected for fusion with it will be ouabain sensitive but can survive and grow in HAT.
- selection for ouabain resistance can be done first either on the parental myeloma line or the hybridoma derived therefrom, followed by back selection or other technique to confer selective destructibility.
- Cells obtained by fusion of the two hybridomas in polyethylene glycol or other fusion agent are transferred to HAT medium containing ouabain in a concentration lethal to the second hybridoma parent.
- the selectively destruc ⁇ tible hybridoma parent cannot survive in the HAT medium either, lacking, for example, the HPRT or other enzyme, even though ouabain resistant.
- the polydoma cells can grow in the medium since they will possess the enzymes and ouabain resistance necessary for survival.
- the foregoing method has the advantage that it is possible to obtain a polydoma by directly fusing a selectively destructible hybridoma parent secreting an antibody having one of the specificities desired in the hybrid with a second, "off the shelf” hybridoma secreting an antibody having the other specificity desired in the hybrid and no use of techniques for conferring selective destructibility on the second hybridoma parent is necessary.
- Yet another technique for obtaining a polydoma which employs a universal parent, i.e., one which has both a positive and a negative marker, which can be fused with any "off the shelf" hybridoma involves the use of recom- binant DNA vectors carrying various drug resistance markers.
- SV40 carrying a gene for neomycin resistance can be used.
- a presently preferred universal parent is one that is HAT sensitive-neomycin resistant.
- the chosen parent is back-selected to HAT sensitivity and then transfected with SV40 vector carrying a gene for neomycin resistance. This procedure can also be reversed with transfection bein done first.
- the resulting hybridoma can grow in th presence of neomycin, which is normally toxic to mammalia cells, but will die in the presence of HAT.
- Off-the-shel hybridomas grow in HAT but die in the presenc of neomycin. Products of the fusion of the parents, therefore, survive in the presence of HAT and neomycin. While the use of vectors to convey resistance to neomyci is presently preferred, vectors carrying genes which wil confer resistance on mammalian cells to other drugs ca also be used.
- the cells obtained from the fusion of hybridomas whose monoclonal antibodies are against differ- ent antigens can be screened using a cytofluorograph to identify the polydomas.
- samples of the two antigens are tagged with different fluorescing moieties whose fluorescence occurs at different wave ⁇ lengths.
- fluorescein and the other rhodamine are incubated with the two tagged antigens.
- Th cells are then screened using the cytofluorograph. Thos cells which fluoresce at only one of the two wavelength 5. will be from the cell lines of the parent hybridomas However, cells which exhibit fluorescence at both wave lengths will be polydomas which can be isolated an subcloned.
- a polydoma can b 0 obtained directly by removing the nucleus from a firs hybridoma which secretes a monoclonal antibody having on of the specificities desired in the hybrid and insertin it into the cytoplasm of a second hybridoma which secrete a monoclonal antibody having the second desired speci 5 ficity.
- neither of the parent hybridomas need to be selectively destructible in order to be used in thi process. After insertion of the nuclear material, th cell is cloned to obtain a population of the polydoma
- polydom cells obtained according to our invention secrete mixture of antibodies, at least one of which is a hybri antibody having a dual specificity. Also produced by th polydoma are relatively smaller amounts of antibodies o the same specificity as those produced by the parent cell used to obtain the polydoma.
- the ratio of hybrid t mono-specific antibodies appears to be about 2:1:1 whic is that expected if the polydoma produces equal amount of all the possible (H) chains synthesized by the paren cells which are randomly combined in the polydoma itself
- the polydomas can be cultured Ln vitro or grow in vivo in either genetically compatible animals or nud mice to obtain large quantities of the hybrid antibod which is recovered from the culture medium or asciti fluid of the animal using known processes. See, fo example, the protocols in "Monoclonal Antibodies", Edite
- the mixture of antibodies produced by the polydo can be resolved to obtain the hybrid.
- simple ion exchan chromatography and electrophoretic techniques can employed as well in at least certain circumstances. required, the charge difference for ion exchange could one of the characteristics of the antibody considered selecting the parental lines.
- Example 1 A hybrid monoclonal antibody having a dual spec ficity for hepatitis B surface antigen (HBsAg) and pr static acid phosphatase (PAP) was- made in accordance wi the present invention in the following manner:
- a hybridoma secreting a monoclonal antibody to P was grown in HAT medium for one week and then transferr to and grown in a non-selective medium. After variou lengths of time of growth under non-selective conditions 2 ml aliquots of cells were placed in medium containin 10-4 M 8-azaguanine which prevented cells from growin by incorporating 8-azaguaine in their DNA instead o guanine. Cells lacking the HPRT enzyme survived and gre in this medium and these cells necessarily did not surviv in HAT.
- Clones that grew in the medium ' containing 8-aza guanine were tested for sensitivity to HAT and anti-PA production.
- One clone which still produced anti-PAP an exhibited HAT sensitivity with a reversion frequency o less than 4 x 10 ⁇ "8 was subcloned. All of the subclone behaved like the parental clone.
- Cells from one of the HAT sensitive subclones were fused in polyethylene glycol with spleen cells obtaine
- Table I show the results obtaine in immunoassays using the ascites obtained from a clone o one of the polydomas compared with ascites obtained fro hybridomas secreting monoclonal antibodies, respectively against IgE (used as a control) , PAP and HBsAg usin immobilized HBsAg as a solid phase and a. variety o radiolabeled antigens as the solution phase.
- the ascites from the polydoma clone bound both labeled HBsAg and labeled PAP, the former attributable to the presence of some non-hy- brid, mono-specific antibody to HbsAg in the ascites and the latter attributable to a hybrid that can bind and bridge the HBsAg on the ball and the trace labeled PAP in solution.
- the experiment using a mixture of labeled PAP and anti-PAP from the parental hybridoma confirms that the anti-PAP specificity of the hybrid is for the same epitope as the antibody secreted by the parent since only background radiation is observed due to inhibition by the parental antibody of binding of labeled PAP to the hybrid antibody.
- HBsAg Material representing each of the DEAE peaks was tested for antigen binding using radiolabeled HBsAg and PAP.
- the first peak bound HBsAg but not PAP.
- the middle peak is hybrid antibody having a dual specificity to HBsAg and PAP comprised of at least two subspecies.
- the hybrid antibody obtained as the middle peak of the DEAE chromatography was radiolabeled with 125 ⁇ . After labeling, 85% of the labeled antibody would bind to PAP and 88% would bind to HBsAg.
- the affinity of the hybrid for PAP was found to be slightly lower than that of the monoclonal antibody to PAP produced by the parental line. This difference in affinity was about the same as that observed by us between a monoclonal antibody and its Fab fragment.
- hybrid antibody comprises more than 50% of the antibodies produced by the polydoma and roughly approximates the ratio 2:1:1 pre- dieted on statistical grounds if the polydoma were to synthesize all the possible antibody heavy chains, i.e., those exhibiting either PAP or HBsAg specificity, which are combined within the cell on a random basis to form hybrid antibody admixed with lesser amounts of the two mono-specific antibodies having the same specificity as those produced by the parent cells.
- the existence of subspecies of hybrid antibody suggests that they ma differ in their light chain composition.
- Hybrid monoclonal antibodies having dual specificit for human IgD and prolactin were made in accordance wit the present invention by the fusion of two hybridomas, on of which was constructed to contain two selectible geneti markers: sensitivity to HAT medium and resistance t ouabain.
- This doubly-marked hybridoma or so-calle "universal parent” could then be fused to any othe hybridoma.
- the resulting polydomas grow in the pre sence of HAT and ouabain, while any unfused parent cell die.
- the advantages of using such a "universal parent have been described elsewhere herein. To construct such a universal parent, both selectibl markers were introduced during initial construction of th hybridoma.
- the widel available HAT-sensitive mouse myeloma P3.653 was selecte for a second genetic marker, ouabain resistance, b introducing 1 mM ouabain into the growth medium. Whil most cells died, approximately 1/100,000 cells had b random mutation acquired resistance to the drug an so survived and multiplied to form the new myeloma popula tion which was HAT-sensitive and ouabain resistant.
- This HAT-sensitive, ouabain-resistant myeloma was then fused with spleen cells obtained from Balb/c mice hyperimmunized with IgD using the previously cited techni ⁇ que of Gerhard.
- Hybrids were selected in HAT medium (without ouabain) and clones were screened for production of monoclonal antibody directed against IgD. From among the positive clones, one which produced an IgG against IgD was selected for further study. This clone was tested for retention of the trait of ouabain resistance by adding 1 mM ouabain to the growth medium. Approximately one- third of the cells retained this genetic marker. When the culture was growing exponentially in ouabain, the cells
- OM were subcloned. Ouabain-resistant subclones were tested for continued production of the monoclonal anti-IgD antibody. One of the subclones was further backselected by the procedure of Example 1 to obtain a population of cells sensitive to HAT. This subclone was grown for two weeks under non-selective conditions and then placed into medium containing 6-thioguanine. As noted above, the mechanism of action of 6-thioguanine is similar to that for 8-azaguanine. Cells which incorporate 6-thioguanine into their DNA instead of guanine will not grow. Cells lacking HPRT enzyme will not utilize 6-thioguanine from the medium and therefore can grow but are consequent ⁇ ly sensitive to HAT.
- This population of the backselected subclone was then itself subcloned in 6-thioguanine and ouabain-containing medium. Subclones were assayed for continued production of the monoclonal anti-IgD antibody.
- One clone which showed all the desired characteristics— growth in ouabain and 6-thioguanine as well as production of monoclonal anti-IgD was selected to be a so-called "universal parent.” This universal parent could then be fused to any other HAT-resistant, ouabain-sensitive hybridoma to produce a polydoma which would express a hybrid antibody, one specificity of which would be anti- IgD.
- mice hybridoma which secretes a monoclonal antibody directed against prolactin.
- the antiprolactin monoclonal antibody is of the same subclass (IgG i) as the anti-IgD ex ⁇ pressed by the parent line and it is easily separated from that antibody on Ornstein-Davis gels. Such a separation is indicative of greatly different charge on the anti ⁇ bodies and so should allow easy isolation of a hybrid antibody by DEAE-Sephadex chromatography.
- a pol styrene bead coated with another anti-prolactin monoclon antibody was incubated 5 hours with 200 U.1 of a 100 ng/ prolaction solution.
- the antibody used binds prolactin a distinct site from that of the antibody produced by t fused hybridoma cell line.
- the bead was washed, th incubated overnight with the clone supernatants. The ne day, following several washes, 125 ⁇ labeled IgD w added.
- Hybrid antibody bound to the bead by one functiono al arm could bind the radiolabeled IgD with the fr anti-IgD functionality whereas neither parental ty antibody IgD-Ig.D or Prolactin-Prolactin could form th bridge between the Prolactin bead and 125 ⁇ -igD trace
- Results of a typical assay for clones producing hybri bifunctional antibody are presented in Table 2 belo
- Anti-Prolactin 8721 21 of 36 clones exhibited significant bifunction activity by this assay. Ascites generated from 2 clon available to date have been shown to react in the bi functional assay. These ascites contain antibodies whi separate into three distinct bands on Ornstein-Davi gels: two bands coincide exactly with antibodies produce by the parent hybridomas (anti-IgD and anti-prolactin) The third band migrates midway between the parenta monoclonal antibody bands as expected of the hybri antibody.
- the hybr antibody can be used as a component of an assay for pr lactin. Tailor-making other hybrid antibodies offe similar opportunities for other assays.
- a CEA solution 600 ng or 25 ng was allowed to adsorb overnight to each well of plastic 96-well microtiter plate. The next day, unad sorbed material was washed out of the wells with PBS-Twee 20. Clone supernatants were added and incubated 2-1/ hours at 35 ⁇ C and then washed off the plate.
- CEA-CEA an CEA-arsenate antibody would remain attached to the plat via the adsorbed antigen.
- the second antigen, arsenyli acid coupled to the enzyme alkaline phosphatase was adde to the wells for 3 hours at 35°C.
- the present invention also provides methods for immunodiagnosis and immunotherapy using antibodies having a dual specificity, for example, hybrid antibodies ob ⁇ tained as described above or from antibody half molecules by the conventional technique of Nisonoff et al, supra, or antibody multimers obtained by coupling or crosslinking individual monospecific antibodies.
- the antibody having a dual specificity used in these methods is a hybrid antibody prepared according to the present invention as such an antibody can be reliably obtained as a substantially pure compound which has not suffered denaturation and which has a uniform specificity and affinity for the antigen.
- an antibody useful in immunohistology would have a first specificity- for a suspect antigen, for example, a tumor associated antigen such as CEA, PAP or ferritin, and a second specificity against a hapten or antigen which will participate in a color reaction such as an enzym which causes a color reaction in the presence of suitable substrate.
- a tumor associated antigen such as CEA, PAP or ferritin
- a second specificity against a hapten or antigen which will participate in a color reaction such as an enzym which causes a color reaction in the presence of suitable substrate.
- suitable enzymes to which th second specificity of the antibody may be directed i prostatic acid phosphatase (PAP) , horse radish peroxidase glucose oxidase, and alkaline phosphatase.
- a tissu section is first treated with the antibody of dual speci ficity. Prior to doing so, the hybrid can have alread been allowed to bind the enzyme which catalyzes th staining reaction. If not, the section is then treate with a second solution containing the enzyme and rinse after an appropriate incubation and then treated with th substrate which undergoes a color change in the presenc of the enzyme. The formation of the color produce by the enzyme and substrate in the tissue sample is positive indication of the presence in the tissue of th target antigen.
- the hybrid antibody against HBsAg and PA whose preparation is described herein, has been found t bind to HBsAg on a test substrate (polystyrene balls) and to PAP in a simulated staining experiment using p-nitro- phenyl phosphate as the enzyme substrate. After incuba ⁇ tion of the hybrid antibody with PAP and the HBsAg, the addition of the p-nitrophenyl phosphate resulted in the balls undergoing the characteristic yellow to brown color change.
- an antibody of dual speci ⁇ ficity can also be used in immunoassays and immunometric assays.
- an immunometric assay for HBsAg can be performed using an immobilized monoclonal antibody to HBsAg as a solid phase to extract HBsAg from a serum or other liquid sample suspected of containing the antigen.
- the sample is incubated with a ball, beads, test tube or other substrate which has the anti-HBsAg bound or coated on its surface.
- the incubation with the serum sample can be followed by, done simulta eously with or preceded by an incubation with a solutio of the hybrid.
- the result will be the formation of a sandwich o the immobilized antibody, HBsAg if present in the sample and the hybrid antibody.
- PAP i permitted to bind with the hybrid antibody. This can b done during or after formation of the sandwich, or in t alternative, the antibody-PAP complex can be preformed After formation of the sandwich, the solid phase is washe to remove sample residue and unbound hybrid antibody a then contacted with a solution containing a substrate suc as p-nitrophenyl phosphate or c ⁇ -napthol phosphate whi undergoes a color change in the presence of PAP. Occu rence of the color change confirms the presence of targe antigen in the sample.
- Th samples used were the positive and negative controls fro the commercial kit and two samples obtained by dilutin the positive control with negative control in the ratio of either 1 part negative control:2 parts positive co trol or 2 parts negative control:1 part positive control
- the bead was washed and incubated with the hybri antibody reactive to both HBsAg and PAP. This allowed sandwich of immobilized antibodies:antigen:and hybri antibody to form.
- the bead was washed again and incubate with a solution of PAP. This incubation was followed b another wash and the bead incubated with a substrat p-napthol phosphate.
- Detection means other than enzymatically catalyzed reactions are also possible.
- the second specificity of the hybrid or other antibody having a dual specificity can be directed against a hapten or antigen which is radiolabeled or which is fluorescent or which is detectable in the sandwich by any other- suitable means.
- a preferred process which utilizes a hybrid antibody or other antibody having a dual specificity in an immuno ⁇ assay exploits the phenomenon of fluorescence quenching.
- one specificity of the antibody is directed against a target antigen and the other against, for example, a hapten bearing a fluorescing chromophore.
- the chromophore is either bound to the hapten or, in appropriate cases, may be the hapten itself.
- the assay is conducted by incubating the antibody with serum or other sample suspected of containing the target antigen to which has been added a predetermined quantity of target antigen labeled with a quenching chromophore.
- the labeled antigen competes with target antigen in the sample, if any, for the antibody binding site specific for the target antigen.
- a quantity of the hapten bearing the fluorescing chromophore is incubated with the antibody and binds at the other binding site.
- the two chromophores are selected so that the first of them fluoresces at a wavelength which can be absorbed (quenched) by the other if they are positioned closely enough together so that the photon emitted by the fluores- cer can be captured by the quencher.
- the two chromophores should be within about 100 angstroms and, preferably, within about 50 angstroms of each other. This positioning will occur when the fluorescing chromophore is bound at one antibody binding site and the quenching chromophore is bound to added antigen at the other.
- a suitable pair of chromophores includes fluorescein as the fluorescing chromophore and rhodamine as the quenching chromophore.
- the measured fluorescence will vary inversely with the amount of native antigen in the sample since, in the absence of native antigen, all of the antigen bound to the antibody will be labeled with the quenching chromo ⁇ phore and be positioned to absorb fluorescence by the chromophore carried by the hapten. Comparison of the measured fluorescence with that of a control sample containing a known amount of antigen permits a qualitative and quantitative determination of the presence of antigen in the sample.
- This kind of immunoassay can, for example, be used to determine the levels in serum of drugs such as dilantin which must be closely monitored.
- the target antigen would, of course, be dilantin.
- this process can be used to detect other antigens as well including, in particular, tumor associated antigens.
- Another preferred process which utilizes a hybri antibody or other antibody having a dual specificity in a immunoassay relies upon an enzymatic reaction.
- one of the antibody speci ficities is directed, of course, to the target antigen an the other to an enzyme or a hapten to which is bound a enzyme.
- the assay is conducted by incubating the antibod with a sample suspected of containing the target antige to which has been added a predetermined quantity of th target antigen that has been modified by binding to it substance that interacts with the enzyme to produce eithe a detectable substance or in some other way to permi detection of formation of the antigen-antibody complex Detection may be, for example, by fluorimetry, lumines cence, spectrophotometry or the like.
- the added target antige may have the enzyme bound to it in which case the antibod has one of its specificities directed against the sub stance which interacts with the enzyme or against a ' hapte to which the substance is bound.
- the substance which interacts with the enzyme can itself be another enzyme.
- one of the enzymes catalyzes production of a product required by the other.
- the antibody binds both the added target antigen, to which is bound one of the enzymes, and the other enzyme, the product of the first enzymatic reaction is formed in proximity to the second enzyme and can undergo a reaction catalyzed by the latter enzyme before significant diffusion of the product into the surrounding medium can occur.
- An example of such a process utilizes the two enzymes hexokinase (HK) and glucose-6-phosphate dehydrogenase (G-6-PDH) in the following reaction scheme.
- HK hexokinase
- G-6-PDH glucose-6-phosphate dehydrogenase
- ATP adenosine diphosphate + glucose-6-phosphate
- the added target antigen will have either HK or G-6-PDH bound to it and the hybrid antibody will have one of its specificities di- rected against the other (or a hapten bearing it).
- the sample has added to it, in addition to the hybrid antibody and the predetermined amount of enzyme labeled antigen, glucose, ATP and the coenzyme NAD + .
- the hybrid antibody preferably has it the other enzyme already bound to it. Alternatively, this enzyme can be added to the sample with the other reagents.
- the enzyme labeled antigen will compete with native antigen in the sample, if any, for one of the hybrid antibody binding sites.
- the other enzyme is or will be, bound to the second binding site.
- the latter converts the glucose-6-phosphate to gluconolactone- 6-phosphate, a result which is .accompanied by the reduc- tion of NAD+ to NADH.
- the NADH absorbs strongly at 340 nm and, therefore, can be detected spectrophotmetrically.
- the amount of NADH formed varies inversely with the amount of native antigen in the sample, i.e., its maximum produc ⁇ tion occurs when there is no target antigen in the sample being assayed. Comparison of the amount of the NADH formed with a control sample permits a qualitative and quantitative determination of the presence of antig in the sample.
- This kind of. assay can be used to monitor the lev of dilantin or other drugs in serum.
- t drug is the target antigen.
- an assay c also be used to detect other serum antigens such as tho associated with tumors or other diseases.
- In vivo immunodiagnosis can also be performed using hybrid or other dual specificity antibody.
- the antibod having one specificity against a target antigen such as tumor associated antigen and the second ' against a hapt to which is bound a suitable radionuclide, preferably o which emits o-radiation, is first administered to the hos After a sufficient time has passed during which t antibody has localized at the target site and unbou antibody has been permitted to clear from healthy tiss in the host, the hapten bearing the radionuclide i administered and binds to the localized antibody. After a suitable interval to permit unbound hapten t clear the host, scanning of the host with a suitabl camera is conducted to determine whether there are area in which radiation has been concentrated.
- This process has several advantages over that .
- the radionuclide In suc cases, the radionuclide must have a long enough half lif that a sufficient quantity remains after the time neces sary for substantial localization of the antibody at th target site has elapsed.
- the antibody may be retained for a period of time in th liver or other non-target tissues which are then subjecte to the radiation carried by the antibody.
- the presen invention permits the use of radio nuclides having shorter half-lives than those used wit monospecific antibodies.
- the radionuclide bearing hapten Being a relatively smal particle, the radionuclide bearing hapten has a hi mobility ⁇ n vivo and will travel rapidly through the ho and either bind to the antibody which has localized at t target site or clear the body without spending appreciab time in non-target tissue. For this reason, isotopes short half-life can be administered in quantities whi pose the minimum risk to healthy tissue even thou administered in substantial excess.
- the hapten is an agent to which t radionuclide is directly bound or which will complex wi the radionuclide.
- a chelating agent for the radionucli bound to a hapten may be used for the latter purpos Those skilled in the art will appreciate that a wi variety of chelating agents and radionuclides are suit for this purpose.
- Phenylarsenate to which ethylen diaminetetraacetic acid (EDTA) is bound as a chelati agent is a suitable hapten.
- a radionuclide suit for use with this hapten is U ln.
- the " antibody of dual specificity can also be used immunotherapy by constructing it to have one specifici against a disease associated antigen and the other again a hapten which is, or to which is bound, an agent leth to -the antigen or diseased tissue with which the antig is associated and which it is desired to destroy.
- the antibody may have one specificity against tumor associated antigen such as PAP, carcinoembryoni antigen (CEA) , ferritin, or other such antigen and second specificity directed to a hapten to which is bou a radionuclide, preferably one which emits or -radi tion, or is comprised of a ricin A chain or other toxi or drug.
- tumor associated antigen such as PAP, carcinoembryoni antigen (CEA) , ferritin, or other such antigen
- the toxin or drug can itself function as a hapten, it ne not be bound to any other moiety.
- the hapten can have t radionuclide bound directly to it or the hapten can be, have bound to it, an agent such as a chelating agent whi will form a complex with the radionuclide.
- a hapten to . which a radionuclide directly bound is 6- 211 At-astato-2-methyl-l,4-napth quinol bis(disodium phosphate) which is described "International Journal of Applied Radiation and Isotopes" 33, 75 (1982).
- the 211&t is an emitter of ⁇ -radiatio
- there a numerous suitable radionuclides which can be bound di rectly to haptens or complexed with a hapten by means any of a wide variety of chelating agents.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50171183A JPS59500696A (en) | 1983-04-12 | 1983-04-12 | Antibodies with bispecificity, their production and their uses |
GB08332646A GB2128631B (en) | 1982-04-12 | 1983-04-12 | Antibodies having dual specificities their preparation and uses therefor |
DK564883A DK564883D0 (en) | 1982-04-12 | 1983-12-08 | DOUBLE SPECIFICITY ANTIBODIES AND THE PREPARATION AND APPLICATIONS THEREOF |
NO834536A NO171643C (en) | 1982-04-12 | 1983-12-09 | ANTIBODIES WITH DOUBLE SPECIFICATIONS, THEIR PREPARATION AND USE |
FI834529A FI834529A0 (en) | 1982-04-12 | 1983-12-09 | ANTIKROPPAR MED DUBBEL SPECIFICITET |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36778482A | 1982-04-12 | 1982-04-12 | |
US367,784820412 | 1982-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1983003679A1 true WO1983003679A1 (en) | 1983-10-27 |
Family
ID=23448582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1983/000525 WO1983003679A1 (en) | 1982-04-12 | 1983-04-12 | Antibodies having dual specificities, their preparation and uses therefor |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0105360A4 (en) |
JP (2) | JPH0753119B2 (en) |
AT (1) | AT394577B (en) |
AU (1) | AU550486B2 (en) |
CA (1) | CA1213229A (en) |
CH (1) | CH672796A5 (en) |
ES (7) | ES521370A0 (en) |
FI (1) | FI834529A0 (en) |
GB (4) | GB2128631B (en) |
IT (1) | IT1219778B (en) |
WO (1) | WO1983003679A1 (en) |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0136835A2 (en) * | 1983-09-01 | 1985-04-10 | Hybritech Incorporated | Process for the preparation of antibody compositions of therapeutic agents having an extended serum half-life |
WO1985004811A1 (en) * | 1984-04-23 | 1985-11-07 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
EP0205198A1 (en) * | 1985-04-29 | 1986-12-17 | Stichting Vrienden Van De Stichting Dr. Karl Landsteiner | Immunological complex, its preparation and its use |
EP0241907A2 (en) | 1986-04-14 | 1987-10-21 | The General Hospital Corporation | Heterobifunctional antibodies and method of use |
FR2604092A1 (en) * | 1986-09-19 | 1988-03-25 | Immunotech Sa | IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO |
WO1988003565A1 (en) * | 1986-11-05 | 1988-05-19 | National Research Development Corporation | Antibodies |
WO1988003566A1 (en) * | 1986-11-05 | 1988-05-19 | National Research Development Corporation | Antibodies |
EP0308936A2 (en) * | 1987-09-23 | 1989-03-29 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
EP0333444A2 (en) * | 1988-03-15 | 1989-09-20 | Synbiotics Corporation | Fast track method for producing monoclonal bi-specific immunoglobuline |
EP0336405A2 (en) * | 1988-04-08 | 1989-10-11 | Takeda Chemical Industries, Ltd. | Anti-human cancer protein complexes, their production and use |
EP0363712A2 (en) * | 1988-09-27 | 1990-04-18 | Takeda Chemical Industries, Ltd. | Hybrid monoclonal antibodies, their production and use |
WO1990012109A1 (en) * | 1989-03-30 | 1990-10-18 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
FR2652004A1 (en) * | 1989-09-21 | 1991-03-22 | Immunotech Partners | NOVEL HYDROPHILIC DERIVATIVES, DIAGNOSTIC AND THERAPEUTIC APPLICATION, DIAGNOSTIC OR THERAPEUTIC KITS AND IMMUNOLOGICAL REAGENTS. |
US5053226A (en) * | 1987-07-15 | 1991-10-01 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
EP0467416A1 (en) * | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
US5141736A (en) * | 1988-12-27 | 1992-08-25 | Takeda Chemical Industries, Ltd. | Bispecific monoclonal antibody, its production and use |
EP0511011A1 (en) * | 1991-04-26 | 1992-10-28 | Surface Active Limited | Novel antibodies and methods for their use |
US5217713A (en) * | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
US5372812A (en) * | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
WO1995004931A1 (en) * | 1993-08-06 | 1995-02-16 | Surface Active Limited | Diagnostic method |
US5453269A (en) * | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
US5496549A (en) * | 1990-04-02 | 1996-03-05 | Takeda Chemical Industries, Ltd. | Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis |
US5501854A (en) * | 1990-02-16 | 1996-03-26 | Boston Biomedical Research Institute | Hybrid reagents capable of selectively releasing molecules into cells |
WO1996012188A1 (en) * | 1994-10-18 | 1996-04-25 | Surface Active Limited | Diagnostic method and apparatus for performing the method |
US5523210A (en) * | 1981-12-21 | 1996-06-04 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US5582862A (en) * | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
US5851527A (en) * | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
US6114506A (en) * | 1996-09-20 | 2000-09-05 | General Hospital Corporation | Composition and method for enhancing fibrinolysis |
WO2005089269A2 (en) | 2004-03-16 | 2005-09-29 | Temple University - Of The Commonwealth System Of Higher Education | Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders |
US7306921B2 (en) | 2001-01-17 | 2007-12-11 | Nevalainen Marja T | Diagnostic and monitoring methods for cancer |
EP2260858A2 (en) | 2003-11-06 | 2010-12-15 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
EP2353611A2 (en) | 2002-07-31 | 2011-08-10 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP2377527A1 (en) | 2007-01-22 | 2011-10-19 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
EP2511299A1 (en) | 2005-04-19 | 2012-10-17 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
EP2609932A2 (en) | 2006-12-01 | 2013-07-03 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
WO2014144871A1 (en) | 2013-03-15 | 2014-09-18 | The Centre For Drug Research And Development | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
WO2016041082A1 (en) | 2014-09-17 | 2016-03-24 | CDRD Ventures, Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP3165237A1 (en) | 2015-11-03 | 2017-05-10 | Industrial Technology Research Institute | Antibody-drug conjugate (adc) and method for forming the same |
EP3248613A1 (en) | 2005-07-18 | 2017-11-29 | Seattle Genetics, Inc. | Beta-glucuronide drug linker conjugates |
EP3505191A1 (en) | 2004-11-12 | 2019-07-03 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
WO2020047306A1 (en) | 2018-08-30 | 2020-03-05 | Innovative Cellular Therapeutics CO., LTD. | Chimeric antigen receptor cells for treating solid tumor |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020229982A1 (en) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
US10918735B2 (en) | 2012-12-04 | 2021-02-16 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
WO2021138264A1 (en) | 2019-12-30 | 2021-07-08 | Seagen Inc. | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
US11319526B2 (en) | 2008-05-02 | 2022-05-03 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
WO2022097117A1 (en) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Ltd. | Antibody drug conjugates |
WO2023278377A1 (en) | 2021-06-29 | 2023-01-05 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
US11844839B2 (en) | 2016-03-25 | 2023-12-19 | Seagen Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1214123A (en) * | 1983-01-20 | 1986-11-18 | Masashi Matsui | Cell lines for use in the preparation of hybridoma cells |
GB2218100A (en) * | 1988-03-02 | 1989-11-08 | Erling Sundrehagen | Conjugates for the detection and/or quantification of antigenic substances in body fluids |
IT1235349B (en) * | 1988-12-23 | 1992-06-30 | Biodata Spa | IMMUNOLOGICAL TEST FOR HOMOGENEOUS DETERMINATIONS |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
US10227407B2 (en) | 2013-10-10 | 2019-03-12 | Yukinari Kato | Anti-podoplanin antibody |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4130634A (en) * | 1974-03-15 | 1978-12-19 | University Of Illinois Foundation | Method for detecting and quantifying antigens |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
EP0068763A2 (en) * | 1981-07-01 | 1983-01-05 | Board Of Regents, The University Of Texas System | Recombinant monoclonal antibodies |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
-
1983
- 1983-04-11 CA CA000425558A patent/CA1213229A/en not_active Expired
- 1983-04-11 ES ES521370A patent/ES521370A0/en active Granted
- 1983-04-12 EP EP19830901672 patent/EP0105360A4/en not_active Ceased
- 1983-04-12 AU AU15559/83A patent/AU550486B2/en not_active Expired
- 1983-04-12 CH CH6700/83A patent/CH672796A5/de not_active IP Right Cessation
- 1983-04-12 WO PCT/US1983/000525 patent/WO1983003679A1/en not_active Application Discontinuation
- 1983-04-12 AT AT0901883A patent/AT394577B/en not_active IP Right Cessation
- 1983-04-12 GB GB08332646A patent/GB2128631B/en not_active Expired
- 1983-04-12 IT IT20548/83A patent/IT1219778B/en active
- 1983-12-09 FI FI834529A patent/FI834529A0/en not_active Application Discontinuation
- 1983-12-12 ES ES527963A patent/ES8503441A1/en not_active Expired
-
1984
- 1984-07-02 ES ES533931A patent/ES8506091A1/en not_active Expired
- 1984-07-02 ES ES533930A patent/ES533930A0/en active Granted
- 1984-10-31 ES ES537257A patent/ES8606655A1/en not_active Expired
- 1984-12-18 ES ES538727A patent/ES8604424A1/en not_active Expired
-
1985
- 1985-07-16 ES ES545247A patent/ES8607386A1/en not_active Expired
- 1985-12-09 GB GB08530309A patent/GB2169921B/en not_active Expired
- 1985-12-09 GB GB08530310A patent/GB2167086B/en not_active Expired
- 1985-12-09 GB GB08530308A patent/GB2168998B/en not_active Expired
-
1987
- 1987-01-05 JP JP62000342A patent/JPH0753119B2/en not_active Expired - Lifetime
-
1994
- 1994-02-10 JP JP6016728A patent/JP2562002B2/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4130634A (en) * | 1974-03-15 | 1978-12-19 | University Of Illinois Foundation | Method for detecting and quantifying antigens |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
EP0068763A2 (en) * | 1981-07-01 | 1983-01-05 | Board Of Regents, The University Of Texas System | Recombinant monoclonal antibodies |
Non-Patent Citations (6)
Title |
---|
Cancer Research 41, June 1981 RASO et al, "Hybrid Antibodies with Dual Specificity for the Delivery of Ricin to Immunoglobulin Bearing Cells" p. 2073-8 * |
Federation Proceedings 37, 1978 p. 1350 Abstract #444 "Hybrid Antibodies as Immunopharmacologic Agents", RASO et al, * |
HERZENBERG et al, "Cell Hybrids of Myelomas with Antibody Forming Cells and T-Lymphomas with T Cells" in "Handbook of Experimental Immunology" Edited by WEIR 1979, BLACKWELL Publications, London, p. 25-1-25, 7 note page 25.5 in particular * |
Proceedings of the National Academy of Sciences (71(6) June 1974, SCHWABER et al "Pattern of Immunoglobulin Synthesis and Assembly in a Human-Mouse Somatic Cell Hybridclone" p. 2203-7 * |
Proceedings of the National Academy of Sciences, 78(9) September 1981, KRANZ et al, "Restricted Reassociation of Heavy and Light Chains from Happen-Specific Monoclonal Antibodies", p. 5807-11 * |
ROSE et al, Principles of Immunology, 2nd Edition MacMILLIAN Publishing Co. NY, 1979 p. 499-507 * |
Cited By (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506135A (en) * | 1981-09-26 | 1996-04-09 | Takeda Chemical Industries, Ltd. | Hybrid monoclonal antibodies, their production and use |
US5523210A (en) * | 1981-12-21 | 1996-06-04 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
EP0136835A3 (en) * | 1983-09-01 | 1986-10-08 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
EP0467416A1 (en) * | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
EP0136835A2 (en) * | 1983-09-01 | 1985-04-10 | Hybritech Incorporated | Process for the preparation of antibody compositions of therapeutic agents having an extended serum half-life |
WO1985004811A1 (en) * | 1984-04-23 | 1985-11-07 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
EP0205198A1 (en) * | 1985-04-29 | 1986-12-17 | Stichting Vrienden Van De Stichting Dr. Karl Landsteiner | Immunological complex, its preparation and its use |
US4868109A (en) * | 1985-04-29 | 1989-09-19 | Lansdorp Peter M | Immunological antibody complex, its preparation and its use |
EP0241907A2 (en) | 1986-04-14 | 1987-10-21 | The General Hospital Corporation | Heterobifunctional antibodies and method of use |
EP0241907A3 (en) * | 1986-04-14 | 1989-09-13 | The General Hospital Corporation | Heterobifunctional antibodies and method of use |
US5453269A (en) * | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
EP0263046A1 (en) * | 1986-09-19 | 1988-04-06 | Immunotech Partners | Affinity enhancement immunological reagents for detection and killing of specific target cells |
US5256395A (en) * | 1986-09-19 | 1993-10-26 | Immunotech Partners | Affinity enhancement immunological reagents for in vivo detection and killing of specific target cells |
FR2604092A1 (en) * | 1986-09-19 | 1988-03-25 | Immunotech Sa | IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO |
WO1988003566A1 (en) * | 1986-11-05 | 1988-05-19 | National Research Development Corporation | Antibodies |
WO1988003565A1 (en) * | 1986-11-05 | 1988-05-19 | National Research Development Corporation | Antibodies |
US5053226A (en) * | 1987-07-15 | 1991-10-01 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
EP0308936A2 (en) * | 1987-09-23 | 1989-03-29 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
EP0308936A3 (en) * | 1987-09-23 | 1990-02-14 | Bristol-Myers Company | Antibody heteroconjugates for the killing of hiv-infected cells |
EP0333444A2 (en) * | 1988-03-15 | 1989-09-20 | Synbiotics Corporation | Fast track method for producing monoclonal bi-specific immunoglobuline |
EP0333444A3 (en) * | 1988-03-15 | 1990-05-23 | Synbiotics Corporation | Fast track method for producing monoclonal bi-specific immunoglobuline |
US6280730B1 (en) | 1988-04-04 | 2001-08-28 | The General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
US5582862A (en) * | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
US5831031A (en) * | 1988-04-04 | 1998-11-03 | The General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
US5372812A (en) * | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
US6576431B2 (en) | 1988-04-04 | 2003-06-10 | The General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
EP0336405A2 (en) * | 1988-04-08 | 1989-10-11 | Takeda Chemical Industries, Ltd. | Anti-human cancer protein complexes, their production and use |
EP0336405A3 (en) * | 1988-04-08 | 1990-05-30 | Takeda Chemical Industries, Ltd. | Anti-human cancer protein complexes, their production and use |
US5851527A (en) * | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
EP0363712A2 (en) * | 1988-09-27 | 1990-04-18 | Takeda Chemical Industries, Ltd. | Hybrid monoclonal antibodies, their production and use |
EP0363712A3 (en) * | 1988-09-27 | 1990-08-16 | Takeda Chemical Industries, Ltd. | Hybrid monoclonal antibodies, their production and use |
US5217713A (en) * | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
US5141736A (en) * | 1988-12-27 | 1992-08-25 | Takeda Chemical Industries, Ltd. | Bispecific monoclonal antibody, its production and use |
WO1990012109A1 (en) * | 1989-03-30 | 1990-10-18 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
US5274076A (en) * | 1989-09-21 | 1993-12-28 | Immunotech Partners | Hydrophilic derivatives, their application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagents |
EP0419387A1 (en) * | 1989-09-21 | 1991-03-27 | IMMUNOTECH PARTNERS: Société en Commandite par Actions dite | Hydrophilic derivatives, diagnostic and therapeutic applications, kits and immunological reagents |
FR2652004A1 (en) * | 1989-09-21 | 1991-03-22 | Immunotech Partners | NOVEL HYDROPHILIC DERIVATIVES, DIAGNOSTIC AND THERAPEUTIC APPLICATION, DIAGNOSTIC OR THERAPEUTIC KITS AND IMMUNOLOGICAL REAGENTS. |
US5501854A (en) * | 1990-02-16 | 1996-03-26 | Boston Biomedical Research Institute | Hybrid reagents capable of selectively releasing molecules into cells |
US5496549A (en) * | 1990-04-02 | 1996-03-05 | Takeda Chemical Industries, Ltd. | Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis |
US5855886A (en) * | 1991-04-26 | 1999-01-05 | Surface Active Limited | Antibodies, and methods for their use |
AU665758B2 (en) * | 1991-04-26 | 1996-01-18 | Surface Active Limited | Novel antibodies, and methods for their use |
AP257A (en) * | 1991-04-26 | 1993-06-03 | Surface Active Ltd | A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. |
WO1992019973A1 (en) * | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
EP0511011A1 (en) * | 1991-04-26 | 1992-10-28 | Surface Active Limited | Novel antibodies and methods for their use |
WO1995004931A1 (en) * | 1993-08-06 | 1995-02-16 | Surface Active Limited | Diagnostic method |
WO1996012188A1 (en) * | 1994-10-18 | 1996-04-25 | Surface Active Limited | Diagnostic method and apparatus for performing the method |
US6114506A (en) * | 1996-09-20 | 2000-09-05 | General Hospital Corporation | Composition and method for enhancing fibrinolysis |
US7306921B2 (en) | 2001-01-17 | 2007-12-11 | Nevalainen Marja T | Diagnostic and monitoring methods for cancer |
US7642050B2 (en) | 2001-01-17 | 2010-01-05 | Nevalainen Marja T | Method for predicting responsiveness of breast cancer to antiestrogen therapy |
EP2353611A2 (en) | 2002-07-31 | 2011-08-10 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP2357006A2 (en) | 2002-07-31 | 2011-08-17 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP3120861A1 (en) | 2003-11-06 | 2017-01-25 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
EP2260858A2 (en) | 2003-11-06 | 2010-12-15 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
EP3858387A1 (en) | 2003-11-06 | 2021-08-04 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
EP2478912A1 (en) | 2003-11-06 | 2012-07-25 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
EP2486933A1 (en) | 2003-11-06 | 2012-08-15 | Seattle Genetics, Inc. | Monomethylvaline compounds conjugated with antibodies |
EP2489364A1 (en) | 2003-11-06 | 2012-08-22 | Seattle Genetics, Inc. | Monomethylvaline compounds onjugated to antibodies |
EP3138832A1 (en) | 2004-03-16 | 2017-03-08 | Temple University - Of The Commonwealth System of Higher Education | Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders |
WO2005089269A2 (en) | 2004-03-16 | 2005-09-29 | Temple University - Of The Commonwealth System Of Higher Education | Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders |
EP3505191A1 (en) | 2004-11-12 | 2019-07-03 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
EP2511299A1 (en) | 2005-04-19 | 2012-10-17 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
EP4026840A1 (en) | 2005-07-18 | 2022-07-13 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
EP3248613A1 (en) | 2005-07-18 | 2017-11-29 | Seattle Genetics, Inc. | Beta-glucuronide drug linker conjugates |
EP2609932A2 (en) | 2006-12-01 | 2013-07-03 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
EP2377527A1 (en) | 2007-01-22 | 2011-10-19 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
US11319526B2 (en) | 2008-05-02 | 2022-05-03 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
US10918735B2 (en) | 2012-12-04 | 2021-02-16 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment |
EP3590922A1 (en) | 2013-03-15 | 2020-01-08 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2014144871A1 (en) | 2013-03-15 | 2014-09-18 | The Centre For Drug Research And Development | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
WO2016041082A1 (en) | 2014-09-17 | 2016-03-24 | CDRD Ventures, Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP4029873A1 (en) | 2014-09-17 | 2022-07-20 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP3165532A2 (en) | 2015-11-03 | 2017-05-10 | Industrial Technology Research Institute | Auristatin derivatives, linker-drugs and ligand-drug conjugates |
EP3165237A1 (en) | 2015-11-03 | 2017-05-10 | Industrial Technology Research Institute | Antibody-drug conjugate (adc) and method for forming the same |
US11844839B2 (en) | 2016-03-25 | 2023-12-19 | Seagen Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020047306A1 (en) | 2018-08-30 | 2020-03-05 | Innovative Cellular Therapeutics CO., LTD. | Chimeric antigen receptor cells for treating solid tumor |
EP3847195A4 (en) * | 2018-08-30 | 2022-09-07 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
WO2020229982A1 (en) | 2019-05-10 | 2020-11-19 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
US11820827B2 (en) | 2019-12-30 | 2023-11-21 | Seagen Inc. | Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies |
WO2021138264A1 (en) | 2019-12-30 | 2021-07-08 | Seagen Inc. | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
WO2022097117A1 (en) | 2020-11-09 | 2022-05-12 | Takeda Pharmaceutical Company Ltd. | Antibody drug conjugates |
WO2023278377A1 (en) | 2021-06-29 | 2023-01-05 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1983003679A1 (en) | Antibodies having dual specificities, their preparation and uses therefor | |
JPH0367678B2 (en) | ||
US4361544A (en) | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers | |
US4460559A (en) | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers | |
EP0035265B1 (en) | Agent for tumor localization and therapy with labeled antibodies and antibody fragments | |
JPS60228962A (en) | Method for simultaneously detecting plurality of antbody | |
Rajagopalan et al. | Novel unconventional binding site in the variable region of immunoglobulins. | |
EP0163041B1 (en) | Diagnostic agent for heart disease and use thereof | |
JPH05184383A (en) | Bispecific antibody | |
WO1990006323A2 (en) | Chimeric proteins incorporating a metal binding protein | |
WO1997011370A1 (en) | Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof | |
JPH0467959B2 (en) | ||
EP0569531B1 (en) | Stabilized antibody fragments | |
JPH0782019B2 (en) | Immunoassay method and immunoassay reagent | |
NO171643B (en) | ANTIBODIES WITH DOUBLE SPECIFICATIONS, THEIR PREPARATION AND USE | |
Martinis et al. | Novel applications of monoclonal antibodies | |
Wood | Monoclonal Antibodies | |
Liu | Development of bispecific monoclonal antibodies and their applications in ultrasensitive virus ELISA: phage display technology and viral purification | |
Nakka | Photomodification of antibodies for radioimmunotherapy and western blot analysis | |
JPS6239772A (en) | Method for quantifying human prolylhydroxylase by radioactive immunoassay | |
JPH08504088A (en) | Tumor-specific antibodies and antigens | |
JPH0424039B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AT AU CH DK FI GB JP LU NO |
|
AL | Designated countries for regional patents |
Designated state(s): BE DE FR NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 834529 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1983901672 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: AT Ref document number: 1983 9018 Date of ref document: 19831027 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1983901672 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 900212 Country of ref document: FI |
|
WWR | Wipo information: refused in national office |
Ref document number: 1983901672 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1983901672 Country of ref document: EP |